Less than 10% of individuals who could benefit from weight-loss injections like Wegovy have access to them, warns the World Health Organization as it publishes its initial advice on the therapies.
With in excess of 1,000,000,000 people worldwide now obese, it is urging broader and more equitable availability to these injectable treatments.
According to forecasts, more than two billion will be obese by 2030 if no action is taken.
"Our latest guidance affirms that obesity is a long-term condition that can be managed with holistic and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major hurdles to broad availability to the treatments that can aid individuals in losing significant weight, explains the agency.
Weight-Loss Drug Scarcity
Even under the present most optimistic scenario, the supply of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The advice encourages nations and manufacturers to expand availability, via approaches including licensing agreements.
A patent on a key compound – the core component of a leading brand – is set to lapse in several countries in 2026.
The Way Weight-Loss Jabs Function
These medications mimick a biological compound to delay gastric emptying, curb appetite and enhance satiety so users reduce food intake.
Patients typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs.
Evidence suggests users may regain a significant portion within a year of discontinuing the treatment, when their normal hunger come back.
To be above a healthy weight increases your likelihood for developing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns individuals in every country and was linked to 3.7 million fatalities worldwide in 2024, as per the health agency.
